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Background: Repair of truncus arteriosus in early
infant period has become standard practice in many cen-
ters. We report the current clinical outcomes of primary
repair of truncus arteriosus in early infancy at a single
institution.
Methods: A retrospective analysis of 31 patients with
mean age 2.6 ± 1.3 months (range, 15 days–6 months),
and mean body weight 3.4 ± 0.6 kg (range, 2.6–4.7 kg)
who underwent primary repair of truncus arteriosus.
Data were collected regarding demographics, anatomy,
operative data, cardiac intensive care unit, and last avail-
able follow-up.
Results: There were four hospital deaths (12.9%);
three of them were due to pulmonary hypertension. At
median follow up of 8 months (range, 1–100 months) after
surgery, there was no late death. One patient was reoper-
ated on for right ventricle-to-pulmonary artery (RV-to-
PA) conduit replacement, residual ventricular septal
defect repair, and truncal valve repair. One patient was
reoperated on twice for truncal valve repair and later
on truncal valve replacement. Three patients required
percutaneous balloon dilation and stenting of pulmonary
artery branches.
Conclusions: Truncus arteriosus can be performed
in early infancy with acceptable perioperative mortality
and morbidity. Pulmonary hypertension continues to be
a risk factor of mortality.
http://dx.doi:10.1016/j.jsha.2012.06.218
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Introduction: Most available data indicates that
stenting for unprotected left main coronary artery dis-
ease (ULMCA) with drug-eluting stents (DES) is safe
and effective. At present, surgery is considered the gold
standard for optimal revascularization.
Objectives: The aim of this study was to evaluate the
short and long term outcome of patients with ULMCA
stenosis who underwent percutaneous coronary inter-
vention (PCI) with DES implantation in a single center.
Methods: Coronary stents were implanted into
ULMCA in 59 patients. Short and long term total mortal-
ity and main adverse cardiac events (MACE): cardiac
death, myocardial infarction and additional target lesion
or non-target lesion revascularization (TLR) were
assessed.
Results: Mean age was 69 ± 13 (29% were females).
23% were emergency/urgent cases. Angiographic and
clinical success of PCI was 100%. 8.5% of the cohort
underwent Transcatheter aortic valve implantation for
severe inoperable aortic stenosis. 52% have significant
distal left main disease requiring two stent bifurcation
techniques. Follow-up duration was 23 ± 13 months.
In hospital MACE occurred in 10%. In hospital death
occurred in 3.4%. Long term total mortality was 11.8%.
3.3% of the cohort died because of non-cardiac problem.
Using ARC (academia and research consortium) defini-
tion, probable acute stent thrombosis occurred in 5% of
the cohort, all of them underwent two stent bifurcation
techniques.
Conclusion: Considering high risk characteristics of
the study group, ULM stenting is feasible, with probably
reasonable short and long term outcomes; however, ULM
stenting requiring two stent bifurcation techniques
should be reserved for patients who are not appropriate
surgical candidates.
http://dx.doi:10.1016/j.jsha.2012.06.219
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Introduction: Clopidogrel has been widely used to
prevent recurrent ischemia in patients with coronary
artery disease. However, inter-individual variability in
response to clopidogrel has been a inconstant in the clini-
cal setting. The aim of the present study was to investigate
the frequency of clopidogrel resistance. There are no data
on the responses to clopidogrel in Saudi Population.
Objectives: We sought to evaluate the response to
clopidogrel among Saudi patients undergoing coronary
angiography.
Methods: Blood samples were drawn at 6–24 h after
a 300/600-mg clopidogrel dose. The degree of inhibition
of platelets was assessed using the VerifyNow assay
(Accumetrics, USA). Patients, who showed 615% inhibi-
tion of platelets or >213 PRU (p2y12 reaction unit), were
defined as non-responders to clopidogrel treatment.
Results: Seventy patients, with mean age of 60.9 ± 11
(29% are female). A wide inter-individual variability was
observed in platelet inhibition (0–64%); 62% patients
showed non response to clopidogrel. There were no dif-
ferences between the patients who responded or not
regarding presence of diabetes mellitus, hypertension,
BMI or concurrent use of proton pump inhibitors.
Conclusion: The response to clopidogrel was highly
variable in Saudi patients with coronary artery disease.
The results of the present study confirmed that in vitro
clopidogrel non-response is frequent. Further follow up
for this cohort to evaluate the clinical impact of it is ongoing.
http://dx.doi:10.1016/j.jsha.2012.06.220
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